Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin. (12th November 2019)
- Record Type:
- Journal Article
- Title:
- Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin. (12th November 2019)
- Main Title:
- Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin
- Authors:
- Cozza, Giorgio
Zonta, Francesca
Dalle Vedove, Andrea
Venerando, Andrea
Dall'Acqua, Stefano
Battistutta, Roberto
Ruzzene, Maria
Lolli, Graziano - Abstract:
- Abstract : Protein kinase CK2 is an antiapoptotic cancer‐sustaining protein. Curcumin, reported previously as a CK2 inhibitor, is too bulky to be accommodated in the CK2 active site and rapidly degrades in solution generating various ATP‐mimetic inhibitors; with a detailed comparative analysis, by means of both protein crystallography and enzymatic inhibition, ferulic acid was identified as the principal curcumin degradation product responsible for CK2 inhibition. The other curcumin derivatives vanillin, feruloylmethane and coniferyl aldehyde are weaker CK2 inhibitors. The high instability of curcumin in standard buffered solutions flags this compound, which is included in many commercial libraries, as a possible source of misleading interpretations, as was the case for CK2. Ferulic acid does not show any cytotoxicity and any inhibition of cellular CK2, due to its poor cellular permeability. However, curcumin acts as a prodrug in the cellular context, by generating its degradation products inside the treated cells, thus rescuing CK2 inhibition and consequently inducing cell death. Through the intracellular release of its degradation products, curcumin is expected to affect various target families; here, we identify the first bromodomain of BRD4 as a new target for those compounds. Database: Structural data are available in the PDB database under the accession numbers 6HOP (CK2α/curcumin), 6HOQ (CK2α/ferulic acid), 6HOR (CK2α/feruloylmethane), 6HOT (CK2α/ferulic aldehyde),Abstract : Protein kinase CK2 is an antiapoptotic cancer‐sustaining protein. Curcumin, reported previously as a CK2 inhibitor, is too bulky to be accommodated in the CK2 active site and rapidly degrades in solution generating various ATP‐mimetic inhibitors; with a detailed comparative analysis, by means of both protein crystallography and enzymatic inhibition, ferulic acid was identified as the principal curcumin degradation product responsible for CK2 inhibition. The other curcumin derivatives vanillin, feruloylmethane and coniferyl aldehyde are weaker CK2 inhibitors. The high instability of curcumin in standard buffered solutions flags this compound, which is included in many commercial libraries, as a possible source of misleading interpretations, as was the case for CK2. Ferulic acid does not show any cytotoxicity and any inhibition of cellular CK2, due to its poor cellular permeability. However, curcumin acts as a prodrug in the cellular context, by generating its degradation products inside the treated cells, thus rescuing CK2 inhibition and consequently inducing cell death. Through the intracellular release of its degradation products, curcumin is expected to affect various target families; here, we identify the first bromodomain of BRD4 as a new target for those compounds. Database: Structural data are available in the PDB database under the accession numbers 6HOP (CK2α/curcumin), 6HOQ (CK2α/ferulic acid), 6HOR (CK2α/feruloylmethane), 6HOT (CK2α/ferulic aldehyde), 6HOU (CK2α/vanillin) and 6HOV (BRD4/ferulic acid). Abstract : Protein kinase CK2 is an antiapoptotic, cancer‐sustaining protein reportedly inhibited by curcumin. However, there is insufficient understanding in the scientific community that curcumin is an unstable molecule that rapidly and spontaneously degrades in aqueous buffers. It is therefore conceivable that a number of its attributed activities are instead caused by its degradation products. Here, we investigate whether its CK2‐inhibiting activities are an example of such an erroneous assignment. … (more)
- Is Part Of:
- FEBS journal. Volume 287:Number 9(2020)
- Journal:
- FEBS journal
- Issue:
- Volume 287:Number 9(2020)
- Issue Display:
- Volume 287, Issue 9 (2020)
- Year:
- 2020
- Volume:
- 287
- Issue:
- 9
- Issue Sort Value:
- 2020-0287-0009-0000
- Page Start:
- 1850
- Page End:
- 1864
- Publication Date:
- 2019-11-12
- Subjects:
- BRD4 bromodomain -- curcumin degradation -- ferulic acid -- protein kinase CK2 -- X‐ray crystallography
Biochemistry -- Periodicals
Molecular biology -- Periodicals
Pathology, Molecular -- Periodicals
572 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=01038983-000000000-00000 ↗
http://www.blackwell-synergy.com/servlet/useragent?func=showIssues&code=ejb ↗
http://onlinelibrary.wiley.com/ ↗
http://www.blackwell-synergy.com/servlet/useragent?func=showIssues&code=ejb ↗ - DOI:
- 10.1111/febs.15111 ↗
- Languages:
- English
- ISSNs:
- 1742-464X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3901.578500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 13289.xml